Zobrazeno 1 - 10
of 31
pro vyhledávání: '"sacha howell"'
Autor:
Sally Anne Pearson, Sally Taylor, Antonia Marsden, Jessica Dalton O’Reilly, Ashma Krishan, Sacha Howell, Janelle Yorke
Publikováno v:
Systematic Reviews, Vol 13, Iss 1, Pp 1-22 (2024)
Abstract Background The review aimed to investigate geographic and sociodemographic factors associated with receipt of systemic anticancer therapies (SACT) for women with secondary (metastatic) breast cancer (SBC). Methods Included studies reported g
Externí odkaz:
https://doaj.org/article/ec85d0c4ad9e43529c8921357cc5ac26
Autor:
Stepan Romanov, Sacha Howell, Elaine Harkness, Megan Bydder, D. Gareth Evans, Steven Squires, Martin Fergie, Sue Astley
Publikováno v:
Tomography, Vol 9, Iss 6, Pp 2103-2115 (2023)
Accurate prediction of individual breast cancer risk paves the way for personalised prevention and early detection. The incorporation of genetic information and breast density has been shown to improve predictions for existing models, but detailed im
Externí odkaz:
https://doaj.org/article/4198fe48becf41f9bd916dfe91a7755f
Autor:
R. C. Coombes, Sacha Howell, Simon R. Lord, Laura Kenny, Janine Mansi, Zahi Mitri, Carlo Palmieri, Linnea I. Chap, Paul Richards, William Gradishar, Sagar Sardesai, Jason Melear, Joyce O’Shaughnessy, Patrick Ward, Pavani Chalasani, Tobias Arkenau, Richard D. Baird, Rinath Jeselsohn, Simak Ali, Glen Clack, Ashwani Bahl, Stuart McIntosh, Matthew G. Krebs
Publikováno v:
Nature Communications, Vol 14, Iss 1, Pp 1-10 (2023)
Abstract Samuraciclib is a selective oral CDK7-inhibitor. A multi-modular, open-label Phase I study to evaluate safety and tolerability of samuraciclib in patients with advanced malignancies was designed (ClinicalTrials.gov: NCT03363893). Here we rep
Externí odkaz:
https://doaj.org/article/b14be29b81754bafad04d4aa37714251
Publikováno v:
Breast, Vol 67, Iss , Pp 71-77 (2023)
Polygenic Risk Scores (PRS) are a major component of accurate breast cancer risk prediction and have the potential to improve screening and prevention strategies. PRS combine the risk from Single nucleotide polymorphisms (SNPs) associated with breast
Externí odkaz:
https://doaj.org/article/5ea44cb843274427b98da44986fe76d6
Autor:
R. C. Coombes, Sacha Howell, Simon R. Lord, Laura Kenny, Janine Mansi, Zahi Mitri, Carlo Palmieri, Linnea I. Chap, Paul Richards, William Gradishar, Sagar Sardesai, Jason Melear, Joyce O’Shaughnessy, Patrick Ward, Pavani Chalasani, Tobias Arkenau, Richard D. Baird, Rinath Jeselsohn, Simak Ali, Glen Clack, Ashwani Bahl, Stuart McIntosh, Matthew G. Krebs
Publikováno v:
Nature Communications, Vol 14, Iss 1, Pp 1-1 (2023)
Externí odkaz:
https://doaj.org/article/4ff05e79a58f49b980db63215fe0a4b3
Autor:
Matthew Winter, Rob Coleman, Jessica Kendall, Carlo Palmieri, Chris Twelves, Sacha Howell, Iain MacPherson, Caroline Wilson, Kash Purohit, Jacqui Gath, Christine Taylor, Richard Eastell, Geraldine Murden, Sarah R. Brown, Emma Rathbone, Janet Brown
Publikováno v:
Journal of Bone Oncology, Vol 35, Iss , Pp 100442- (2022)
Background: Approximately 70% of patients with metastatic breast cancer (MBC) develop bone metastases. Despite advances in systemic treatment options and the use of bone targeted agents in the management of bone metastases to reduce skeletal morbidit
Externí odkaz:
https://doaj.org/article/f4c9910e2ee343c2970db1a4f3955768
Autor:
Narendra Nath Basu, James Hodson, Shaunak Chatterjee, Ashu Gandhi, Julie Wisely, James Harvey, Lyndsey Highton, John Murphy, Nicola Barnes, Richard Johnson, Lester Barr, Cliona C. Kirwan, Sacha Howell, Andrew D. Baildam, Anthony Howell, D. Gareth Evans
Publikováno v:
Scientific Reports, Vol 11, Iss 1, Pp 1-10 (2021)
Abstract Contralateral risk-reducing mastectomy (CRRM) rates have tripled over the last 2 decades. Reasons for this are multi-factorial, with those harbouring a pathogenic variant in the BRCA1/2 gene having the greatest survival benefit. On May 14th,
Externí odkaz:
https://doaj.org/article/5688cd59f9bd429381b2e9941fc6d5dd
Autor:
Rob Coleman, Janet Brown, Emma Rathbone, Louise Flanagan, Amber Reid, Jessica Kendall, Sacha Howell, Chris Twelves, Carlo Palmieri, Anjana Anand, Iain MacPherson, Sarah Brown
Publikováno v:
Trials, Vol 21, Iss 1, Pp 1-10 (2020)
Abstract Background A substantial proportion of breast cancer patients develop metastatic disease, with over 450,000 deaths globally per year. Bone is the most common first site of metastatic disease accounting for 40% of all first recurrence and 70%
Externí odkaz:
https://doaj.org/article/f23455173b0d42049b53d3ddcd09b49b
Autor:
D. Gareth Evans, Sacha Howell, Fiona Lalloo, Christopher McHague, Andrew Shenton, Stephen A. Roberts, Ayshe Latif, Kristen D. Hadfield, William G. Newman
Supplementary Table S1 from Impaired Tamoxifen Metabolism Reduces Survival in Familial Breast Cancer Patients
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::47f5f095adf560f7c4d8d2853cf1694d
https://doi.org/10.1158/1078-0432.22439733
https://doi.org/10.1158/1078-0432.22439733
Autor:
D. Gareth Evans, Sacha Howell, Fiona Lalloo, Christopher McHague, Andrew Shenton, Stephen A. Roberts, Ayshe Latif, Kristen D. Hadfield, William G. Newman
Purpose: Tamoxifen has been the mainstay adjuvant hormonal treatment for breast cancer for many years. Conversion of tamoxifen to its active metabolite, endoxifen, is reduced by low activity of the cytochrome P450 enzyme, CYP2D6. We examined the effe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::197ea27e58fb95313bf6385af46e2dab
https://doi.org/10.1158/1078-0432.c.6517161.v1
https://doi.org/10.1158/1078-0432.c.6517161.v1